Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. - Trial NCT06059261
Access comprehensive clinical trial information for NCT06059261 through Pure Global AI's free database. This Phase 2 trial is sponsored by Chongqing University Cancer Hospital and is currently Not yet recruiting. The study focuses on Nasopharyngeal Carcinoma. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Envafolimab and recombinant human endostatin combined with chemoradiotherapy
Interventional
drug
Sponsor & Location
Chongqing University Cancer Hospital
Timeline & Enrollment
Phase 2
Oct 01, 2023
Oct 01, 2027
Primary Outcome
Progress-free survival (PFS)
Summary
This is a single-center, prospective, single-arm, phase II clinical study, with the purpose
 to evaluate the therapeutic efficacy and safety of envafolimab combined with
 chemoradiotherapy and recombinant human endostatin in patients with locally advanced
 nasopharyngeal carcinoma.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06059261
Non-Device Trial